CompletedNCT01876810
Gemfibrozil and Responses to Smoking-Related Cues
About this title
Read the official source — NCT01876810Medication studyAges 19–65CanadaAddiction
Understand this study
Who was this study for?
Listed age limits: 19 years to 65 years.
- Listed locations
- Toronto and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateFebruary 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 28
- Sponsor
- Centre for Addiction and Mental Health
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 19 Years to 65 Years
- Official registry ID
- NCT01876810
- Official title
Show the full official title
Testing the PPAR Hypothesis of Nicotine Dependence in Humans: Gemfibrozil as a Novel Treatment for Tobacco Addiction
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Gemfibrozil and Placebo.
Who was this study for?
Listed age limits: 19 years to 65 years.
